An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma
- To obtain a preliminary estimate of the progression-free survival at 1 year after
allogeneic hematopoietic stem cell transplantation.
- To determine the speed of neutrophil and platelet recovery post allograft.
- To assess the incidence and speed of donor-derived engraftment post allograft.
- To assess the incidence and severity of acute graft-vs-host disease (GVHD) at 100 days
- To determine the incidence and severity of chronic GVHD at 1 year post allograft.
- To assess the incidence of transplant-related mortality at 100 and 180 days post
- To assess the incidence of relapse or disease progression at 1 and 2 years post
- To determine the probabilities of overall survival at 1 and 2 years post allograft for
all patients undergoing allograft.
- To determine the probabilities of progression-free survival at 2 years post allograft
for all patients undergoing allograft.
- To assess the number of patients enrolled on the intention-to-treat study proceeding to
- To determine the probabilities of overall and progression-free survival at 1 and 2
years for all patients on the intention-to-treat study.
- To assess the performance of laboratory studies investigating double unit biology and
their correlation with unit engraftment in the patient.
OUTLINE: Patients are stratified according to response to prior therapy and risk factors
(those with presence of all 3 risk factors and failed primary therapy or primary progressive
disease vs. patients who relapse more than 100 days after an autologous stem cell
- Salvage chemotherapy (IGV or MOPP): Patients who have previously received
mechlorethamine hydrochloride receive IGV; patients who have previously received a
gemcitabine-based regimen receive MOPP.
- IGV (ifosfamide, gemcitabine hydrochloride, and vinorelbine ditartrate): Patients
receive IGV combination chemotherapy comprising ifosfamide IV on days 1-4,
gemcitabine hydrochloride IV on days 1 and 4, and vinorelbine ditartrate IV on day
1. Treatment repeats every 2-3 weeks for 2-3 courses in the absence of disease
progression or unacceptable toxicity.
- MOPP (mechlorethamine hydrochloride, vincristine, procarbazine hydrochloride, and
prednisone): Patients receive MOPP combination chemotherapy comprising
mechlorethamine hydrochloride IV on days 1 and 8, vincristine IV on days 1 and 8,
oral procarbazine hydrochloride on days 1-14, and oral prednisone on days 1-14.
Treatment repeats every 4 weeks for at least 2 courses in the absence of disease
progression or unacceptable toxicity.
Patients with no progression of disease after salvage chemotherapy (at allograft work-up)
proceed to allogeneic hematopoietic stem cell transplantation [AHSCT]* within 60 days after
completion of salvage chemotherapy.
NOTE: *Patients with a nodal mass > 5 cm that has not ben previously irradiated and in the
absence of extranodal disease may undergo involved-field radiotherapy twice daily for 2
weeks, prior to AHSCT.
- AHSCT with reduced-intensity or non-myeloablative conditioning: Patients achieving
partial response or stable disease after salvage therapy receive fludarabine phosphate
IV over 30 minutes on days -6 to -2; melphalan IV over 15 minutes on days -6 and -5;
and undergo AHSCT on day 0 (reduced-intensity conditioning). Patients achieving
complete response after salvage therapy receive fludarabine phosphate IV over 30
minutes on days -6 to -2; cyclophosphamide IV over 15 minutes on day -6; total-body
irradiation over 20-30 minutes on day -1; and undergo AHSCT on day 0 (non-myeloablative
- Graft-vs-host disease prophylaxis: Patients with related or unrelated donors receive
cyclosporine IV over 2-4 hours or orally on days -3 to 100 followed by a taper,
mycophenolate mofetil IV or orally on days -3 to 46 followed by a taper, and
methotrexate IV on days 1, 3, 6, and 11.
Patients who received umbilical cord blood receive cyclosporine and mycophenolate mofetil as
above (no methotrexate).
After completion of study treatment, patients are followed at 6, 9, and 12 months and then
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival at 1 year
Miguel-Angel Perales, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|